Pharmaceuticals News and Research

RSS

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients - estimated to be as many as 1 million in the U.S. - drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

26 May 2011

Neoprobe, Devicor sign gamma detection device asset purchase agreement

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has signed a definitive asset purchase agreement to sell its neoprobe GDS line of gamma detection device systems to Devicor Medical Products, Inc. for $30 million in cash, plus a contingent value provision for payment to Neoprobe of up to an additional $20 million in royalties.

26 May 2011

Lx Therapies, BioCis partner to form Laurantis Pharma

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.

26 May 2011

Watson announces acquisition of Specifar Pharmaceuticals

Watson Pharmaceuticals, Inc. and Specifar Pharmaceuticals S.A. today jointly announced that Watson has acquired the privately-held multinational generic pharmaceutical developer, manufacturer and marketer for EUR 400 million in cash and certain contingent consideration.

25 May 2011

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Comtex SmarTrend has ranked POZEN as the second most efficient company in the pharmaceutical industry.

25 May 2011

Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that in the follow-up portion of its Phase 2 clinical trial in patients with diabetic foot ulcers, the percentage of patients treated with the therapeutic dose of DSC127 with complete healing at 24 weeks following trial enrollment was 73% in the intent-to-treat population and 85% in the per-protocol population, a difference of 27 and 33 percentage points, respectively, compared with patients treated with placebo/standard of care.

25 May 2011

Pharmaceutical Executive's Ad Stars, DTC Perspectives recognize Auxilium and Heartbeat work

Heartbeat Ideas' and Auxilium Pharmaceuticals' ad campaign for Auxilium's Low Testosterone Therapy has been recognized as one of the top consumer advertisements of the year by Pharmaceutical Executive's Ad Stars and the DTC Perspectives National Ad Awards.

25 May 2011

AFP examines expansion of Indian drug companies in South Africa

Agence France-Presse examines how Indian drug companies have infiltrated the South African market over the last few years in an effort to have a broader reach in Africa. India's pharmaceutical industry is now the second largest in the world by volume, according to AFP.

25 May 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Novartis announced results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid used to treat gouty arthritis attacks.

25 May 2011

China Nepstar Chain Drugstore first quarter revenue increases 9.0% to US$94.4 million

China Nepstar Chain Drugstore Ltd., the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the first quarter ended March 31, 2011.

25 May 2011

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

PsychoGenics Inc. today announced that it has entered into a strategic alliance with Evotec AG to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

25 May 2011

Idera Pharmaceuticals' preclinical data on novel GSO technology presented at TIDES 2011

Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data of its novel gene-silencing oligonucleotide technology including observations that demonstrate GSOs exert gene-silencing activity through a similar cellular pathway as siRNA.

25 May 2011

BPD expands existing bioprocess and scale-up laboratory in Poway, CA

Biologics Process Development Inc., a wholly-owned subsidiary of Viropro, will double the size of its existing bioprocess- and scale-up laboratory in Poway, CA.

25 May 2011

New study shows that closing schools, other measures limited H1N1 spread in Mexico

The H1N1 virus was new, and most of the cases occurred among young people. Health professionals and scientists weren’t sure at the onset what the world would encounter with the virus.

24 May 2011

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis. PH-10, an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin, is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis.

24 May 2011

Provepharm obtains European marketing authorization for its Methylthioninium Chloride Proveblue

Provepharm, a biotech start-up specialized in the development of pharmaceutical applications, announces today that it has just received official marketing authorization for its Methylthioninium Chloride Proveblue from the European Medicines Agency. This authorization means that clinicians will be able to treat European patients for the first time with this injectable drug based on the active principal methylthioninium chloride Proveblue (TM) (or methylene blue), which embodies the quality and safety characteristics currently required of a pharmaceutical product.

24 May 2011

Valeant to acquire Sanitas for EUR314 million

Valeant Pharmaceuticals International, Inc. today announced that it has agreed to acquire AB Sanitas for approximately EUR314 million in cash.

24 May 2011

Nestle Health Science to acquire Prometheus Laboratories

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that it has entered into a definitive agreement to be acquired by Nestle Health Science S.A., a wholly-owned subsidiary of Nestle S.A., for an undisclosed amount.

24 May 2011

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

The U.S. Food and Drug Administration today approved Incivek treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

24 May 2011

Pharmaceuticals News and Research

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

Neoprobe, Devicor sign gamma detection device asset purchase agreement

Lx Therapies, BioCis partner to form Laurantis Pharma

Watson announces acquisition of Specifar Pharmaceuticals

Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company

Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks

Pharmaceutical Executive's Ad Stars, DTC Perspectives recognize Auxilium and Heartbeat work

AFP examines expansion of Indian drug companies in South Africa

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

China Nepstar Chain Drugstore first quarter revenue increases 9.0% to US$94.4 million

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

Idera Pharmaceuticals' preclinical data on novel GSO technology presented at TIDES 2011

BPD expands existing bioprocess and scale-up laboratory in Poway, CA

New study shows that closing schools, other measures limited H1N1 spread in Mexico

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Provepharm obtains European marketing authorization for its Methylthioninium Chloride Proveblue

Valeant to acquire Sanitas for EUR314 million

Nestle Health Science to acquire Prometheus Laboratories

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence